Skip to main content

Table 1 Demographic and disease characteristics between the usual care and feasibility participants

From: Electronic patient-reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study

 

Audit (Before) N = 45a

Feasibility (After) N = 24

Hospital site

 Hospital A

17 (37.8%)

8 (33.3%)

 Hospital B

28 (62.2%)

16 (66.7%)

Age

 Median (range), years

62.3 (41.9-85.4)

62.8 (21.0-78.7)

Marital Status, n (%) b

 Married / Civil Partnership

28 (62.2%)

17 (70.8%)

 Co-habiting

4 (8.9%)

1 (4.2%)

 Separated / Divorced

4 (8.9%)

2 (8.3%)

 Widowed

2 (4.4%)

1 (4.2%)

 Single

2 (4.4%)

3 (12.5%)

Employment, n (%)c

 Full time

9 (20.0%)

2 (8.3%)

 Part time

2 (4.4%)

4 (16.7%)

 Unable to work

4 (8.9%)

1 (4.2%)

 Retired

23 (51.1%)

15 (62.5%)

 Unemployed (not looking)

3 (6.7%)

0

 Student

0

1 (4.2%)

Education, n (%)c

 Basic school

11 (24.4%)

6 (25.0%)

 Beyond minimum school leaving age

12 (26.7%)

7 (29.2%)

 Degree or professional qualification

18 (40.0%)

10 (41.7%)

Diagnostic stage:

 Stage 1C/2

8 (17.8%)

5 (20.8%)

 Stage 3A/3B

5 (11.1%)

4 (16.6%)

 Stage 3C

20 (44.4%)

14 (58.3%)

 Stage 4

12 (26.7%)

1 (4.2%)

Origin of cancer:

 Ovary

26 (57.8%)

16 (66.7%)

 Peritoneal

9 (20.0%)

4 (16.7%)

 Fallopian

10 (22.2%)

4 (16.7%)

Histology:

 Serous

37 (82.2%)

20 (83.3%)

 Clear cell

3 (6.7%)

2 (8.3%)

 Endometriod

2 (3.5%)

0

 Mucinous

1 (1.8%)

2 (8.3%)

 Mixed

1 (1.8%)

0

 Unknown

1 (1.8%)

0

Tumour grade:

 Poorly differentiated

39 (86.7%)

19 (79.2%)

 Other (e.g. moderate, well differentiated)

4 (8.9%)

4 (16.7%)

 Unknown

2 (4.4%)

1 (4.2%)

BRCA status:

 No abnormality

32 (71.1%)

19 (79.2%)

 BRCA confirmed

7 (15.6%)

2 (8.3%)

 Not tested

6 (13.3%)

3 (12.5%)

Time since last treatment completed:

 Median (Range), days

39.0 (4-153)

412.5 (32-3262)

  < 12 months

45 (100%)

11 (45.8%)

  > 12 months

0

13 (54.2%)

Number (%) who relapsed during the study period:

24 (53.5%)

7 (29.2%)

 Median months to relapse (patient being informed) since last treatment end

6

13

 Range (min-max)

10 (2-12)

44 (5-49)

Baseline QOL outcomes, mean (s.d):

 FACT-O total score, possible range: 0-152

118.9 (18.11)

122.2 (24.77)

 FACT-G score, possible range: 0-108

85.6 (14.61)

88.3 (19.30)

- Physical subscale, possible range: 0-28

23.3 (3.79)

24.8 (3.33)

- Social subscale, possible range: 0-28

24.3 (4.26)

23.3 (7.70)

- Emotional subscale, possible range: 0-24

17.7 (4.58)

18.2 (5.31)

- Functional subscale, possible range: 0-28

20.3 (5.57)

22.0 (6.68)

 EQ 5D-VAS, possible range 0-100

78.7 (13.49

84.7 (13.52)

 QLACS fear of recurrence subscale, possible range 4-28

14.2 (6.20)

13.8 (5.91)

 Self-efficacy total score, possible range 6-60

47.8 (10.81)

49.2 (11.68)

 PAM 13 score, possible range 0-100

61.7 (13.67)

64.6 (15.68)

  1. aThree audit participants did not return the baseline demographic/computer use questionnaire.
  2. bTwo audit participants did not answer the marital status questions.
  3. cOne further audit participant and one feasibility participant did not answer the employment and education questions.
  4. Abbreviations: FACT-O Functional Assessment Cancer Therapy-Ovarian, FACT-G Functional Assessment Cancer Therapy-General, EQ. 5D-VAS, EuroQol 5 Dimension Visual Analog Scale, QLACS Quality of Life in Adult Cancer Survivors, PAM Patient Activation Measure